8-K filed August 14, 2024, 7:59 PM ET ticker ACTU CIK 0001652935

other material confidence high sentiment positive materiality 0.85

Actuate Therapeutics completes IPO of 2.8M shares at $8.00, net proceeds $19.2M

ACTUATE THERAPEUTICS, INC.

IPO closed Aug 14, 2024: 2,800,000 shares at $8.00/share, net proceeds $19.2M.
Underwriters granted 30-day option to purchase up to 420,000 additional shares.
New independent directors appointed: Jason Keyes, Roger Sawhney, Amy Ronneberg; Les Kreis resigned.
Charter amended: authorized common stock increased to 200M shares; classified board created.
Exclusive forum provisions for federal securities law claims adopted in charter.

item 5.02 item 5.03 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Amy Ronneberg

Director

ACTU · ACTUATE THERAPEUTICS, INC.

Effective: 2024-08-14
Filed: August 14, 2024, 7:59 PM ET

each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.

Appointed

Jason Keyes

Director

ACTU · ACTUATE THERAPEUTICS, INC.

Effective: 2024-08-12
Filed: August 14, 2024, 7:59 PM ET

each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.

Appointed

Roger Sawhney

Director

ACTU · ACTUATE THERAPEUTICS, INC.

Effective: 2024-08-14
Filed: August 14, 2024, 7:59 PM ET

each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.

Departed

Les Kreis, Jr.

Director

ACTU · ACTUATE THERAPEUTICS, INC.

Effective: 2024-08-14
Filed: August 14, 2024, 7:59 PM ET

Les Kreis, Jr. resigned from the Board effective immediately prior to the closing of the Company’s initial public offering.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Ronneberg was appointed as Director at ACTUATE THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Keyes was appointed as Director at ACTUATE THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Roger Sawhney was appointed as Director at ACTUATE THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Les Kreis, Jr. resigned as Director at ACTUATE THERAPEUTICS, INC..

Action: resigned
Role: Director

Exact text from the filing

Les Kreis, Jr. resigned from the Board effective immediately prior to the closing of the Company’s initial public offering.

View on SEC.gov

ACTUATE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-089693

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.